ES005 / Elpiscience - LARVOL DELTA

Interactions of substrates and phosphinyl containing inhibitors with bacterial and human zinc proteases. (PubMed, PLoS One) - "The MD simulations of ES005 with TLN showed that the MALDI-TOF MS results could be explained by that a Phe in S1' subpocket generate more stable interaction with TLN than an Ala in that subpocket. The docking studies indicated that the size of the S1' subpocket is an important determinant for inhibitor selectivity between bacterial and human zinc MPs."

Journal • MMP14 • MMP9

High-affinity anti-LAG3 MAb from Elpiscience Biopharma enhances antitumor activity of T cells in preclinical studies (Bioworld) - "Elpiscience Biopharma Ltd.’s ES-005 is a new high-affinity monoclonal antibody (MAb) that blocks human lymphocyte-activated gene 3 (LAG3) from binding to several ligands, such as major histocompatibility complex class II (MHC-II), liver and lymph node sinusoidal endothelial cell C-type lectin (L SECtin) and fibrinogen like 1 (FGL1)."

Preclinical • Oncology

Elpiscience Announces Studies Presented at SITC 2022 Annual Meeting (Businesswire) - "Elpiscience Biopharmaceuticals...presented positive studies for its innovative immunotherapeutic molecules at the SITC 2022 Annual Meeting....Abstract No.: 426...Highlights: (i) ES005 potently blocks LAG3 binding to multiple ligands including FGL-1; (ii) ES005 effectively reverses LAG3 driven inhibition of T cell activation; (iii) ES005 monotherapy potently inhibits tumor growth in EMT6 syngeneic tumor model; (iv) ES005 was well tolerated in cynomolgus monkeys with favorable PK Profile."

Preclinical • Oncology • Solid Tumor

ES005, a high affinity anti-LAG3 monoclonal antibody, inhibits the interactions between LAG3 and multiple ligands and enhances anti-tumor activity of T cells in preclinical models (SITC 2022) - "Conclusions In summary, anti-LAG3 mAb ES005 is a multiple-ligand blocker and demonstrated potent single-agent activity in in vivo mouse tumor models, indicating great potential to be used as next-generation immune checkpoint inhibitor in cancer treatment. We are currently advancing the development of ES005 into clinical candidate."

IO biomarker • Preclinical • Breast Cancer • Oncology • Solid Tumor • CD4 • CD8 • CTLA4 • FGL1 • HLA-DRB1 • PD-1

Elpiscience Announces Five Poster Presentations at Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting (Businesswire) - "Elpiscience Biopharmaceuticals...announced it will have five poster presentations at the SITC 2022 Annual Meeting being held in Boston, Massachusetts from November 8-12. The posters will highlight studies on five innovative molecules including anti-SIRPα monoclonal antibody ES004, anti-LAG3 monoclonal antibody ES005, anti-LILRB2 monoclonal antibody ES009, anti-SIGLEC15 antibody ES012, and PD-L1/SIRPα bispecific macrophage engager ES019."

Preclinical • Oncology

Alkalibacter rhizosphaerae sp. nov., a CO-utilizing bacterium isolated from tidal flat sediment, and emended description of the genus Alkalibacter. (PubMed, Int J Syst Evol Microbiol) - "is proposed. The type strain is ES005 (=KCTC 25246=JCM 34530)."

Journal • CAT